Cross Creek is a venture capital firm that primarily focuses on late-stage, pre-IPO venture-backed companies, typically within 2-4 years of going public, to capture value creation that has shifted to private markets. They also employ a fund-of-funds strategy, investing in leading venture capital firms and "focus managers" to gain broader market access and exposure to sectors like biotech where they don't make direct investments.
Portfolio
7
Fund Size
$1.5B
Top Stage
Series C
Last 12 Mo
3
Team
Stage Distribution
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| onX | Growth | — | Nov 2025 |
| onX | Unknown | — | Nov 2025 |
| WeTravel | Series C | $78M | Sep 2025 |
| Sardine | Series C | $70M | Feb 2025 |
| Fictiv | Series E | $100M | May 2022 |
| Carrum Health | Series A | $40M | Jan 2021 |
| Icertis | Series E | $115M | Jul 2019 |
Top Co-Investors
TCV2 shared
Activant Capital1 shared
Andreessen Horowitz1 shared
Nyca1 shared
GV (Google Ventures)1 shared
Geodesic Capital1 shared
Sapphire Ventures1 shared
Left Lane Capital1 shared
Base10 Partners1 shared
Westly Group1 shared
Accel1 shared
G2 Venture Partners1 shared
Standard Investments1 shared
Greycroft1 shared
B Capital1 shared
Eight Roads Ventures1 shared
Ignition Partners1 shared
Meritech Capital1 shared
PSP Growth1 shared
Tiger Global Management1 shared
Last updated: 1 March 2026